Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

As I wrote in my last note on Structure: The most famous examples of GLP-1 agonist drugs are Novo Nordisk's (NVO) semaglutide - approved to treat Type 2 Diabetes ("T2D") under the brand name ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The exorbitant costs of drugs like Wegovy — especially compared to other countries — have prompted some insurers to tighten ...

While furosemide and other diuretics can help with symptoms, the drugs that have had a very significant impact on the ...

In its annual 'Measuring the Return from Pharmaceutical Innovation' report based on the top 20 pharma companies by 2020 R&D ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Despite the widespread benefits of GLP-1 agonists as an obesity treatment ... “When I start these brand name medications, part of my consent process for these meds is a discussion with my ...